Form D · Biotechnology
Immunome Inc.
Exton, MA · CIK 0001472012
Offering snapshot reported May 11, 2021 · SEC filing
- Reported sold
- $27M Offering amount: $27M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 11, 2021 | Initial | $27,000,054 | No comparison | Not reported | SEC filing |
| Jun 16, 2020 | Amendment | $11,000,000 | No comparison | 49 | SEC filing |
| Jun 1, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 19, 2019 | Initial | $9,300,000 | No comparison | 35 | SEC filing |
| May 29, 2019 | Amendment | $6,500,000 | No comparison | 27 | SEC filing |
| Feb 1, 2019 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 30, 2017 | Initial | $5,000,000 | No comparison | 48 | SEC filing |
| Jul 14, 2016 | Initial | $5,057,508 | No comparison | 27 | SEC filing |
| Dec 2, 2015 | Initial | $3,634,048 | No comparison | 18 | SEC filing |
| Apr 13, 2015 | Amendment | $892,500 | $425,000vs Oct 14, 2014 | 17 | SEC filing |
| Oct 14, 2014 | Initial | $467,500 | No comparison | 14 | SEC filing |
| Mar 19, 2014 | Amendment | $735,000 | $535,000vs Mar 3, 2014 | 23 | SEC filing |
| Mar 3, 2014 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Feb 20, 2013 | Initial | $445,000 | No comparison | 9 | SEC filing |
| Jan 27, 2012 | Initial | $145,000 | No comparison | 4 | SEC filing |
| Jun 8, 2011 | Amendment | $846,631 | $400,000vs Oct 5, 2010 | 5 | SEC filing |
| Oct 5, 2010 | Amendment | $446,631 | $0vs Oct 4, 2010 | 2 | SEC filing |
| Oct 4, 2010 | Amendment | $446,631 | $100,000vs May 3, 2010 | 2 | SEC filing |
| May 3, 2010 | Initial | $346,631 | No comparison | 2 | SEC filing |
| Sep 14, 2009 | Initial | $435,356 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-399003
Source: Form D, filed May 11, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Baron | Director |
| Scott Dessain | Executive |
| Dennis H Giesing | Executive |
| Gregory Harriman | Director |
| George Hobbs | Executive |
| Jane H. Hollingsworth | Director, Executive |
| David Kutcher | Executive |
| John La Mattina | Director |
| Joan Lau | Executive |
| Michael Lefenfeld | Director |
| Gregory P. Licholai | Director |
| Michael J Morin | Executive |
| I Wistar Morris | Director |
| I. Wistar Morris | Director |
| Timothy J. Pelura | Executive |
| Michael D Rapoport | Director |
| Michael Rapp | Director |
| Corleen Roche | Executive |
| Purnanand Sarma | Director, Executive |
| Barbara S. Schilberg | Director |
| Sandra G Stoneman | Executive |
| Joel Sussman | Executive |
| Philip Wagenheim | Director |
| Michael D Widlitz | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
665 Stockton Drive Suite 300
Exton, MA, 19341
Exton, MA, 19341